Table 2.

Pharmacokinetic Parameters by Noncompartmental Analysis of Tacrolimus Administered Alone or in Combination With Voriconazole According to CYP2C19 Genotype

	CYP2C19 Genotype
	EM (n = 6)		IM (n = 6)		PM (n = 6)
	Alone	With Voriconazole	Alone	With Voriconazole	Alone	With Voriconazole
Tmax (h)	1.5 ± 0.5	2.3 ± 1.5	1.7 ± 0.8	2.3 ± 0.5	1.8 ± 0.4	2.8 ± 0.8 *
Cmax (ng/mL)	18.3 ± 7.9	48.3 ± 16.6 *	20.5 ± 12.5	54.9 ± 12.0 *	16.3 ± 5.7	60.5 ± 16.7 *
AUC0‐24 (ng · h/mL)	88.3 ± 53.1	389.5 ± 111.9 *	108.2 ± 79.7	540.6 ± 110.1 * , #	94.8 ± 29.1	570.5 ± 134.9 * , #
Ratio of AUC0–24 with voriconazole to alone	─	4.4	─	5.0	─	6.0

EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.

Data are shown as the mean ± SD.

^* P < .05 compared to tacrolimus alone for each corresponding CYP2C19 genotype as assessed using the Wilcoxon matched‐pairs signed‐rank test.

^# P < .05 compared to the CYP2C19 EM genotype when coadministered with voriconazole as assessed using the Wilcoxon rank‐sum test.